Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Go back to Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)| (NASDAQ: SVRA) | Delayed: 5.69 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.69 | 52 Week High | $ | |||
| Open | $5.69 | 52 Week Low | $ | |||
| Day High | $5.69 | P/E | N/A | |||
| Day Low | $5.69 | EPS | $ | |||
| Volume | 858 | |||||
